Authors
Latest:
Web-Based Exercises Effective in Improving Cognitive Impairment Following ChemotherapyPatients with symptoms of cognitive impairment who practiced web-based memory and mental processing exercises over a period of 15 weeks experienced marked improvement in their cognitive function.
Latest:
Nivolumab Alone or With Ipilimumab Controls Disease, Extends Survival, in MesotheliomaNivolumab as monotherapy or in combination with ipilimumab may present a new second- or third-line treatment option for patients with malignant pleural mesothelioma, based on preliminary findings from a phase II trial where nivolumab alone or in the combination improved disease control and prolonged survival in patients with this rare but aggressive cancer.
Latest:
Hepatocellular Carcinoma Surveillance in FocusControversy over optimal surveillance methods for hepatocellular carcinoma continues to drive ongoing investigation into improved biomarkers and imaging techniques.
Latest:
Dr Nye on Paradigm Shifts in the Management of HR+ Breast CancerLauren E. Nye, MD, discusses how the expansion of targeted therapies in metastatic hormone receptor–positive breast cancer has shifted management approaches.
Latest:
Dr. Pinter-Brown Discusses Treatment Decisions for CTCLLauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses the treatment of cutaneous T-cell lymphoma.
Latest:
Experts Emphasize Therapy Options, Expanded Mutation Testing in mCRCConfusion persists about the best choice of frontline therapy for patients with metastatic colorectal cancer (mCRC) after a landmark clinical trial that was conceived a decade ago to answer that question concluded without a superiority finding
Latest:
Dr. Albiges on Next Steps for Immunotherapy in RCCLaurence Albiges, MD, ‎medical oncologist, head, Genitourinary Oncology Unit, Gustave Roussy, discusses the next steps for immunotherapy for patients with renal cell carcinoma (RCC).
Latest:
Summary and Forward Looking for RCCIn her concluding remarks, Laurence Albiges, MD, PhD, shares her final thoughts and expresses optimism for the future landscape of renal cell carcinoma treatments.
Latest:
Dr. Heifetz Discusses Rural Oncology CareLaurence J. Heifetz, MD, medical director, Gene Upshaw Memorial Tahoe Forest Cancer Center, discusses rural oncology care.
Latest:
Dr. Gaspar on a Physician Survey on Prophylactic Cranial Irradiation in SCLCLaurie E. Gaspar, MD, professor, Radiation Oncology, University of Colorado Denver, discusses a survey she conducted for physicians on the use of prophylactic cranial irradiation for patients with limited small cell lung cancer.
Latest:
Dr. Gaspar on Treating Brain Metastases in Lung CancerLaurie Gaspar, MD, professor and chair of the Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses the treatment of brain metastases in patients with lung cancer.
Latest:
Future Directions and Unmet Needs in Relapsed/Refractory MCLA panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.
Latest:
Dr. Parsons Discusses the Role of PARP 7 in Overall Survival of Patients With Ovarian CancerLavanya Palavalli Parsons, MD, clinical fellow, The University of Texas Southwestern Medical Center, discusses the role of PARP 7 in overall survival of patients with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.
Latest:
What I Have Learned Since Fellowship: Tips for Professional Success and HappinessTips for success from Lawrence B. Afrin, MD an associate professor of medicine in the Division of Hematology/Oncology at Medical University of South Carolina in Charleston.
Latest:
A Comprehensive Review of Hemibody Irradiation for Patients with Bone MetastasesA comprehensive review was initiated on hemibody irradiation for patients with solid tumors with an emphasis on bone metastases to determine the efficacy and the toxicity of this treatment.
Latest:
Dr. Kaplan on Research With Bispecific Monoclonal Antibodies in Follicular LymphomaLawrence D. Kaplan, MD, discusses research with bispecific monoclonal antibodies in follicular lymphoma.
Latest:
Dr. Feldman on Lenvatinib and Pembrolizumab Plus Chemotherapy in NSCLCLawrence E. Feldman, MD, discusses the phase 3 LEAP-006 trial evaluating lenvatinib and pembrolizumab plus chemotherapy in non–small cell lung cancer.
Latest:
Dr. Lawrence Fong on Managing the Side Effects of ImmunotherapiesLawrence Fong, MD, Professor, Department of Medicine (Hematology/Oncology), University of California San Francisco, discusses the importance of educating oncologists on the side effects of immunotherapies.
Latest:
Dr. Einhorn on Improving the Cure Rate and the Burden of Cure in Prostate CancerLawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses new methods being explored to help improve the cure rate in prostate cancer.
Latest:
Hereditary Prostate Cancer—What Urologists Should KnowHistorically, urologists have been the primary caretakers for men with localized prostate cancer, which is the most prevalent solid tumor in men over 50 years of age and the second-leading cause of cancer-specific mortality in the United States today.
Latest:
Dr. Schneiderman on Rationing Medical CareLawrence J. Schneiderman, MD, professor emeritus, Medicine/Family & Preventive Medicine, University of California, San Diego (UCSD), discusses preparing doctors for the fact that medical care will have to be rationed in the future.
Latest:
Dr. Solin on Personalizing Treatment With the DCIS ScoreDr. Lawrence Solin from Einstein Medical Center on Personalizing Treatment With the DCIS Score
Latest:
Dr. Karsh on the TERRAIN Trial for Prostate CancerLawrence Karsh, MD, FACS, director, Clinical Research Department, The Urology Center of Colorado, discusses the TERRAIN trial, which compared enzalutamide with bicalutamide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Latest:
Dr. Lawrence Mayer on CPX-351 for Acute Myeloid LeukemiaLawrence Mayer, PhD, president, founder and chief scientific officer of Celator Pharmaceuticals, explains the technology behind CPX-351, a liposomal formulation of cytarabine and daunorubicin. CPX-351 was recently granted Fast Track Designation by the FDA for the treatment of elderly patients with relapsed acute myeloid leukemia (AML).
Latest:
Dr. Shulman on Chemotherapy in Adjuvant Breast CancerLawrence N. Shulman, MD, chief of staff, senior vice president for medical affairs, director, Center for Global Cancer Medicine, director, Department of Regional Strategy and Development, chief, Division of General Oncology, Dana-Farber Cancer Institute, discusses chemotherapy choices for patients with adjuvant breast cancer.
Latest:
Dr. Lekakis on Managing the Toxicity of CAR T-Cell TherapyLazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses managing the toxicity of CAR T-cell therapy.
Latest:
Dana-Farber Tackles Rising Incidence of Young-Onset Colorectal CancerDana-Farber Cancer Institute launched the Young-Onset Colorectal Cancer Center, among the first of its kind, in March 2019 to provide expert and compassionate clinical care, promote scientific discovery and innovation to elucidate underlying biological mechanisms, identify risk factors, and facilitate development of novel therapies, and improve prevention and early detection by raising public awareness of the rising burden of CRC in young adults.
